We take a look at directors buying and selling shares in their own company in our weekly column.
- Non-exec buys shares in Aquis Exchange
- CEO buys shares in Oncimmune
- Dr Martens non-execs purchase shares
Here’s why Director Dealings can play an important role in stock-picking
Non-exec buys shares in Aquis Exchange
Aquis Exchange LON:AQX Non Executive Director, Fields Wicker-Miurin has purchased 2,450 shares in the company at 407p each for a total consideration of £9,971.5. The AIM listed creator and facilitator of next-generation financial markets has today (Tuesday 6th) launched its new ‘Dark to Lit Sweep’ functionality within its subscription based Aquis Markets division to provide members with easier access to liquidity and find the best possible price across both order books, while keeping market impact low. This follows on from some ‘punchy’ numbers for the full year back at the end of March, with the Group seeing a 24% increase in net revenue. Bridgewise rates the stock as a ‘Buy’.
At the time of writing, shares were trading at 408p, up 7.4% for the year to date and -9.1% over the last 12 months.
CEO buys shares in Oncimmune
Oncimmune Holdings LON:ONC Chief Executive Officer, Dr Adam Mark Hill, has purchased 48,370 shares in the Company at a price of 20.6533p per share for a total consideration of £9,990. The AIM listed antibody profiling company released interims last week with revenues sharply lower after contract delays. However, the company is undertaking a pivot, having sold one business and acquired another and management are committed to reaching cashflow breakeven in the near term.
Shares in the company were trading at 22.58p, down 58% this year and down 77% over the last 12 months.
- Three Quick Facts: Direct Line, Loungers, Dr Martens
- Aquis Exchange and Cboe in bid to fill consolidated tape role in Europe
- Aquis shares up over 100% on SIX acquisition news
Dr Martens non-execs purchase shares
Dr Martens LON:DOCS Non Executive Director Andrew Harrison has bought 18,374 shares in the company at a price of 135.3136p for a total cost of £24,862. In addition, Non Executive Director Lynne Weedall purchased 4,000 shares at 135.6p each for a total consideration of £5,424. The iconic footwear and clothing brand released final results last week with revenues breaking above £1bn for the first time. Management noted some strategic errors having been made in its US division which appears to be holding back the share price. Bridgewise rates the stock as a ‘Hold’.
Share were trading at 131.32p, down 33% for the year to date and -51% over the last 12 months.
